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Triple Threat
In a mouse model that mimics sclero-
dermatous graft-versus-host disease 
(Scl-GVHD), Morin and colleagues 
demonstrated that treatment with 
the epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitor erlo-
tinib results in decreased EGFR phos-
phorylation; improved disease severity 
scores; decreased ear pinna thickness; 
decreased cellular infiltration; reduced 
transaminase levels; lower IFN, IL-13, 
and CCL17 levels; and decreased mem-
ory CD4+ T- and autoimmune B-cell activation. These findings indicate that inhibition 
of EGFR phosphorylation impacts the three main Scl-GVHD components of fibrosis, 
inflammation, and autoimmunity, and they highlight the potential for use of erlotinib 
in the treatment of chronic GVHD in humans. See page 2385
It’s BRAF Again
Syringocystadenoma papilliferum (SCAP), 
which rarely undergoes transforma-
tion, can arise spontaneously as a soli-
tary lesion or appear in a linear pattern 
at birth. Whole-exome sequencing of 
affected tissue/blood from a 12-year-
old otherwise healthy girl with such 
linear plaques revealed a single dam-
aging somatic variant in BRAF, which 
is mutated in about 50% of melanomas 
and in colon, lung, and ovarian can-
cers. Following validation in other patients, Levinsohn and colleagues suggest consid-
eration of transformation to carcinoma and the risk of internal malignancy in patients 
with large mosaic SCAP lesions at birth and that therapeutics that target BRAF mutants 
may prove beneficial for patients with unresectable SCAP tumors. See page 2536
Soft Cell
Keratins, which comprise the major epidermal cytoskel-
eton constituents, determine cell stiffness. Homberg 
and colleagues examined the effects of mutations in ker-
atin 14 (K14p.Arg125) and keratin 5 (K5p.Glu477Asp), 
which are frequently mutated in the severe blistering 
disease epidermolysis bullosa simplex (EBS). The K14 
mutation resulted in impaired desmosomes, compro-
mised desmosomal adhesion, and weakened epithelial 
sheet integrity, whereas the K5 mutation failed to cause 
these effects. Furthermore, the K14 mutation reduced 
the stiffness of keratinocytes in a dominant-negative 
manner. Together, these findings suggest that reduced cell stiffness and intracellular 
adhesion contribute to the pathogenesis of EBS, marking these mechanisms as pos-
sible targets for EBS therapies. See page 2437
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Scratch the Surface 
of Itch
Because chronic itch is often 
intractable, the identifica-
tion of major factors and 
mechanisms is paramount 
for the development of novel 
treatment options. Patricio 
and colleagues reported that 
activation of proteinase-
activated receptor-4 (PAR-4) 
by a selective agonist (AYP) 
induces itchlike behavior 
that depends on AYP action 
on sensory neurons in the 
skin. Transient receptor 
potential vanilloid-1 and 
transient receptor potential 
ankyrin-1 channels are likely 
activated, resulting in release 
of itch-mediating neurotrans-
mitters by neurons. Thus, 
PAR-4 antagonists represent 
a promising avenue for the 
development of antipruritic 
drugs. See page 2484
Just a Little Tweak
Via interaction with its recep-
tor Fn14, tumor necrosis fac-
tor (TNF)-like weak inducer 
of apoptosis (TWEAK) 
induces apoptosis of kerati-
nocytes. Interestingly, Cheng 
and colleagues reported that 
high expression of these fac-
tors occurs with infection 
with human papillomavirus 
(HPV) type 16. In addition, 
activation of TWEAK/Fn14 
concomitant with expression 
of the E6/E7 HPV oncopro-
tein, which contributes to 
immortalization of kerati-
nocytes in association with 
HPV carcinogenesis, induced 
proliferation, but not apopto-
sis, of keratinocytes. Because 
elevated levels of Fn14 have 
previously been observed in 
keratinocyte-originated can-
cers, Fn14 is a promising tar-
get for the treatment of such 
cancers. See page 2427
